Shutterstock photo
Markets

Wednesday’s best web

Shutterstock photo

Shutterstock photo

Wednesday's best web reviews a telecom deal in Mexico, the generic drug market in India, the case for Samsung to make a bid for Nokia, the health of the Indonesian rupiah, and the TAPI pipeline project.

[caption align="alignright" caption="Expect the TAPI pipeline to not be without incident, if it ever gets built anyway"] Public domain image [/caption]

Alexandros Petersen writing for the Foreign Policy AFPAK blog delves into the TAPI pipeline project

Best web: The TAPI pipeline plans to take natural gas from Turkmenistan and transport it to India via Afghanistan and Pakistan. Petersen wonders when the collaborators will stop planning and expanding and start building. The planned route is more than ambitious enough. Especially when one realizes the pipeline has no choice but to negotiate a conflict zone.

Reuters reports Iusacell and Telefonica are rumored to havemade a deal to share telecommunication infrastructure

Best web: Mexican media and telephone provider Iusacell has reached a deal with Telefonica ( TEF , quote ) to be revealed Wednesday in Mexico City. Analysts suspect the two companies will share infrastructure to help tamp down costs and enable them to better compete with undisputed Mexican mobile leader America Movil ( AMX , quote ).

Jonathan Yates of Emerging Money makes the case for Samsung to acquire Nokia

Best web: South Korea's Samsung ( SSNLF , quote ) is rumored to be contemplating a bid to acquire Nokia corporation ( NOK , quote ). Yates makes the case for the purchase citing Nokia's ties to Microsoft ( MSFT , quote ), emerging market presence, and cheap valuation. Not to forget, Nokia is the second largest seller of mobile phones in the world.

The Times of India reports on the bourgeoning market for generic drug producers

Best web: With the expiration of patents for popular drugs Lipitor, Plavix and Zyprexa, Indian generic drug companies are scrambling to get first-to-file rights and cash in. Companies can expect to earn several hundred million dollars for being the first generic approved. Analysts say another $30 billion of drug patents will expire this year with a total of $60 billion expiring by 2015.

Ben Bland of beyondbrics discusses the Indonesian central bank's effort to support the rupiah

Best web: Indonesia's central bank held interest rates steady at 5.75% despite concerns about the worsening global economy. Indonesia's foreign exchange reserves are falling, an unfortunate side effect of being an "open" market. Currency traders and speculators are not optimistic in the short term as short positions on the rupiah have increased of late.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Other Topics

Stocks